# Synthesis and Pharmacological Activity of 3-[(p-Acetamidoalkyl) benzenesulfonyl]-thiazolidin-4-ones and Thiazolines

Hamad A. Al-Khamees<sup>1</sup>, Hesham A. Kandil<sup>1</sup>, Kamal E.H. El-Tahir<sup>2</sup> and Said M. Bayomi<sup>1</sup>

<sup>1</sup>Department of Pharmaceutical Chemistry and <sup>2</sup>Department of Pharmcology, College of Pharmacy, P.O. Box 2457, King Saud University, Riyaddh-11451, Saudi Arabia

(Received September 5, 1992)

Two series of substituted sulfonylthiazolidin-4-ones and sulfonylthiazolines have been synthesized and examined for their antidiabetic and biological aticity.

Key words: Thioureas, Antidiabetic, Condensation, Cardiaovascular

#### INTRODUCTION

Many compounds such as carboxylic acid derivatives (Bott-Handford and Heath, 1981), imidazolidine-2,4-diones (Peterson et al., 1979), oxazolidine-2,4-diones (Bott-Handford and Heath, 1980) and some 5-benzylthiazolidine-2,4-diones (Sohda et al., 1982) are previously reported to possess hypoglycemic activity. Based on the structral analogy of these compounds, the synthesis and biological evaluation of two series of compounds, specifically 2-alkylimino-3-[(p-acetamidoalkylbenzenesulfonyl]] thiazolidin-4-ones 14-21 and 2-alkylimino-3-(p-acetamidoalkylbenzenesulfonyl]-4-(p-bromophenyl)thiazolines 23-30 were undertaken during the course of our search for a novel antidiabetic agents.

#### **EXPERIMENTAL**

Melting points were determined with Mettler FP5 melting point apparatus and are uncorrected. Nuclear magnetic resonance spectra were determined in deuterochloroform or DMSO-d<sub>6</sub> with a Varin FT 80 A and XL 200 Spectrometers, Infrared spectra (KBr) were taken on a Perkin-Elmer 580B Spectrometer. Analysis of compounds for C, H, and N were carried out with Perkin-Elmer 240B elemental analyser. The chemical used are commerically available (Fluka, Switzerland and Aldrich Co., U.S.A.).

### N-\p-(2-Acetamidoethyl)benzenesulfonyl]-N'-alkyl-thioureas 9-13

The procedure given for the synthesis of 10 is a

Correspondence to: Said M. Bayomi, Department of Pharmaceutical Chemistry, College of Pharmacy, P.O. Box 2457, King Saud University, Riyaddh-11451, Saudi Arabia

general method for the synthesis of 9-13 Table I. A mixture of p-(2-acetamidoethyl)benzenesulfonamide 24 (3.50 g, 0.041 mol) and anhydrous potassium carbonate (5.90 g, 0.043 mol) in dry acetone (100 ml) was stirred and refluxed for 1.5 h, At this temperature, a solution of methyl isothiocyanate (1.60 g, 0.0216 mol) in dry acetone (20 ml) was then added at a dropwise rate. After stirring and refluxing overnight the mixture was cooled and filtered. The solid residue was dissolved in water (375 ml) and acidified with 6N-hydrochloric acid. The crude product precipitated was purified by recrystallization from ethanol to give white crystals. See Table I. IR (KBr)  $cm^{-1}$ ; 3240 (NH), 1620 (C=S), 1345 & 1125 (SO<sub>2</sub>). NMR (DMSO-d<sub>6</sub>): 1.79 (s, 3H, COCH<sub>3</sub>), 2.83 (t, 2H, benzylic protoins), 2.91 (d, 3H, HN-CH<sub>3</sub>), 3.32 (m, 2H, CONH-CH<sub>2</sub>, 7.44-7.89 (m, 4H, aromatic protons), 7.90 (s, 1H, NHCO), 8.6 (broad s, 1H, CSNH) and 11.75 (broad s, 1H, SO<sub>2</sub>NH).

## 2-Alkylimino-3-(p-acetamidoalkylbezenesulphonyl) thiazolidin-4-ones, 14-21

The procedure given for the synthesis of **14** is a general route for the synthesis of **14-21**. A mixture of thiourea **10** (2.83 g, 0.01 mol), sodium acetate (2 g) and chloroacetic acid (1.03 g, 0.011 mol) in absolute ethanol (30 ml) was refluxed for overnight. The solid precipitated after cooling was collected by filtration and washed with water and air dried. Recrystallization from ethanol gave white crystals of **18**, See Table II; IR (KBr) cm<sup>-1</sup>: 3390 (NH), 1720 (thiazolidone C=O); 1620; (C=N); 1400 & 1140 (SO<sub>2</sub>); NMR (DMSO-d<sub>6</sub>) &: 1.78 (s, 3H, CH<sub>3</sub>-CO), 2.79 (t, 2H, benzylic protons); 3.02 (s, 3H, =N-CH<sub>3</sub>), 3.31 (m, 2H, NH-CH<sub>2</sub>-); 4.08 (s, 2H, C<sub>5</sub>-H), 7.46-4.82 (m, 4H, aromatic protons); and 7.92 (broad s, NHCO).

**Table I.** N-[p-(2-acetamidoethyl)benzenesulphonyl]-N'-alkylthioureas 6-13

Comp. No.	R	Yield %	mp. ℃	Molecular formula	Analysis % o	calcd (found)	N
6-9*	0.1				,		
10	-CH₃	77	152-153	$C_{12}H_{17}N_3O_3S_2$	45.69(45.88)	5.43(5.38)	12.32(13.37)
11	-CH <sub>2</sub> -CH <sub>3</sub>	75	126-127	$C_{13}H_{19}N_3O_3S_2$	47.39(47.22)	5.81(5.77)	12.76(12.61)
12	$-(CH_2)_3-CH_3$	82	99-100	$C_{15}H_{23}N_3O_3S_2$	50.39(50.17)	6.48(6.47)	11.75(11.71)
13	$\leftarrow$	82	148-150	$C_{17}H_{25}N_3O_3S_2$	53.24(52.89)	6.57(6.50)	10.96(10.61)

<sup>\*</sup>Are prepared according to the reported procedure (Boutwell, 1961).

Table II. 2-alkylimino-3-(p-acetamidoalkylbenzenesulfonyl)thiazolidin-4-ones 14-21

Comp. No.	R		n Yield % mp. °C Mol	···· %	Malanda famada	Analysis % calcd (found) C H N		
		f 1		Molecular Iormula	C	Н	Ν	
14	-CH <sub>3</sub>	1	70	180-81	C <sub>13</sub> H <sub>15</sub> N <sub>3</sub> O <sub>4</sub> S <sub>2</sub>	45.73(45.59)	4.43(4.51)	12.30(12.08)
15	-CH <sub>2</sub> -CH <sub>3</sub>	1	82	173-174	$C_{13}H_{19}N_3O_3S_2$	47.39(47.22)	5.81(5.77)	12.76(12.61)
16	-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	1	67	118	$C_{16}H_{21}N_3O_4S_2$	50.11(49.30)	5.52(5.90)	10.96(10.85)
17	$\leftarrow$	1	82	186	$C_{18}H_{23}N_3O_4S_2$	52.79(52.88)	5.66(5.90)	10.24(10.25)
18	-CH₃	2	77	171	$C_{14}H_{17}N_3O_4S_2$	47.30(47.47)	4.82(4.81)	11.82(11.40)
19	-CH₂CH₃	2	89	121	$C_{15}H_{19}N_3O_4S_2$	48.76(48.58)	5.18(5.28)	11.37(11.30)
20	-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	2	78	118	$C_{17}H_{23}N_3O_4S_2 \cdot H_2O$	49.14(49.01)	6.06(5.89)	10.11(10.15)
21	$\leftarrow$	2	90	162	$C_{19}H_{25}N_3O_4S_2 \cdot H_2O$	51.60(51.70)	6.16(5.97)	9.52 (9.20)

### 2-Alkylimino-3-(p-acetamidoalkylbenzenesulfonyl)-4-(p-bromo-phenylthiazoline, 22-29

The procedure given for the synthesis of **26** is a general method for the preparation of **22-29**. A mixture of thiourea **10** (2.83 g, 0.01 mole) and p-bromophenacyl bromide (2.8 g, 0.01 mol) in isopropyl alcohol (30 ml) was refluxed for 4 hr. The alcohol was evaporated in vacuo and the residue was washed with 10% sodium acetate and then extracted with chloroform ( $30 \times 3$ ). The organic extract was washed with water and dried with anhydrous sodium sulphate. The oily product obtained after the evaporation of chloroform was dissolved in the least amount of ethyl acetate and n-hexane was added till turbid solution and then kept in refrigerator for overnight. The solid obtained on scratching was collected and washed with n-hexane and air dried.

Recrystallization from acetone gave white crystals of 26, See Table III; IR (KBr) cm $^{-1}$ : 3240 (NH) 1625 (C=O), 1300 & 1140 (SO<sub>2</sub>); NMR (DMSO-d<sub>6</sub>)  $\delta$ : 1.79 (s, 3H, CH<sub>3</sub>-CO); 2.77 (t, 2H, benzylic protons); 3.33 (m, 3H, -NH-CH<sub>2</sub>-); 3.39 (s, 3H, =N-CH<sub>3</sub>), 6.94 (s, 1H, C<sub>5</sub>-H); (m, 7.35 & 7.80 (m, 4H aromatic protons); and

7.95 (broad s, 1H, NH).

#### **METHOD**

## Recording of the electrocardioggram (ECG) and measurement of the heart rate

Male wister rats (300g, body weight) were anesthetized with urethane, 1.25g Kg<sup>-1</sup> i.p (25%, w/v aqueous solution) and left in spontaneous respiration. The electrocardiogram (ECG; Lead II or III) was recorded using subcutaneous steel needle limb electrodes connected to a Narco Physiograph fitted with an ECG coupler No. 7176 (Narco Bio-systems) as outlined previously (Eltahir et al., 1989). The speed of the chart was adjusted to 10 mm Sec-1. The heart rate was calculated from the QRS complexes per unit time. The test compounds were dissolved in dimethyl sulfoxide (DMSO). Each does was dissolved in 50 µl DMSO and injected i.v. via a canula inserted into the right external jugular vein. In each experiment DMSO alone (0.167 ml/Kg) was initially injected i.v. into the anaesthetized rat and its effect on the heart rate was quantified as a percentage decrease compared to the normal heart rate of

Table III. 2-alkylimino-3-(p-acetaminoalkylbenzenesulfonyl)-4-(p-bromophenyl)thiazolines 22-29

Comp. No.	R	n	Yield %	mp. ℃	Molecular formula	Analysis % o		
						C	Н	N
22	-CH₃	1	71	189	C <sub>19</sub> H <sub>18</sub> BrN <sub>3</sub> O <sub>3</sub> S <sub>2</sub>	45.73(45.59)	4.43(4.51)	12.30(12.08)
23	-CH <sub>2</sub> -CH <sub>3</sub>	1	47	151	$C_{20}H_{20}BrN_3O_3S_2$	48.58(48.28)	4.08(4.28)	8.50(7.78)
24	-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	1	52	137	$C_{22}H_{24}BrN_3O_3S_2$	50.57(50.13)	4.63(4.66)	8.04(7.84)
25	-	1	74	134	$C_{24}H_{26}BrN_3O_3S_2$	52.55(52.87)	4.78(5.15)	7.66(7.60)
26	-CH <sub>3</sub>	2	73	148	$C_{20}H_{20}BrN_3O_3S_2$	48.58(47.96)	4.07(4.15)	8.50(8.42)
27	-CH <sub>2</sub> -CH <sub>3</sub>	2	67	141	$C_{21}H_{22}BrN_3O_3S_2$	49.60(50.09)	4.36(4.49)	8.26(7.97)
28	-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	2	60	94	$C_{23}H_{26}BrN_3O_3S_2$	51.49(51.30)	4.88(4.93)	7.83(8.18)
29	$\leftarrow$	2	67	141	$C_{21}H_{22}BrN_3O_3S_2$	49.60(50.00)	4.36(4.49)	8.26(7.97)

the test animal. This effect was then subtracted from the effect observed following administration of the solubilized test compound. The values reported in this paper are the net effects induced by the test compound. All compounds were tested in the dose range 3.75-15  $\mu$ mol Kg<sup>-1</sup>. Each animal was used to test only one compound (n/4 animals for each dose).

#### Chemistry

Thiazolidin-5-ones 14-21 and thiazolines 22-29 listed in tables 2 & 3 were synthesized from the corresponding thioureas derivatives 6-13 as shown in Scheme 1

The starting thioureas **6-13** were obtained by chlorosulphonation reaction of N-benzylacetamide **1** and N-phenethylacetamide **2** followed by treatment with ammonia to afford the corresponding sulfonamide derivatives **3** & **4** (Hoechst, 1965). Whereas condensation of **3** with alkyl isothiocyanates **5** in refluxing alcohol using pyridine as a basic catalyst gave the thiourea derivatives **6-9** in good yields (El-Kerdawy and El-Kousy, 1975). Thiourea derivatives **10-13** were obtained in high yields by the condensation of sulfonamides **4** with alkyl isothiocyanates **5** in refluxing dry acetone and in the presence of anhydrous potassium carbonate, see experimental section and Table I.

The infrared spectra of thiourea derivatives **6-13** displayed -NH- and -C=S stretching bands at 3400-3420 and 1390-1380 cm<sup>-1</sup>, respectively, in addition to the characteristic sulphone bands at 1350-1300 and 1115-1100 cm<sup>-1</sup>.

Condensation of thiourea derivatives 6-13 with  $\alpha$ -chloroacetic acid in ethyl alcohol containing anhydrous sodium acetate afforded the target 3-( $\rho$ -acetamidoalkyl-

benzenesulfonyl) thiazolidin-4-ones **14-21** in very good yields as shown in Table II. The possibility of formation of the alternative structure **30** is ruled out on the basis of TLC study and the hydrocholytic reactions of compound **17** obtained by the condensation N-[(p-(2-acetamidoethyl)benzenesulfonyl]-N'-cyclohexylthiourea **13** and chloroacetic acid. The TLC investigation indicated the formation of only one product, and the acid hydrolysis of compound **17**, resulted in the isolation of the cyclohexylamine as a major hydrolytic product, in addition to several other unidentified products. The structural assignment of these compounds was further established by the microanalytical as well as spectral data, see the experimental section.

On the other hand, reaction of thiourea derivatives 6-13 with *p*-bromophenacylbromide in refluxing isopropyl or ethyl alcohol gave the desired 3-(4-acetamidoalkylbenzenesulfonyl)thiazolines 23-29 in good yields as shown in Table III. Evidence for the formation of compounds 22-29 was supported from the IR spectra where the thioamido bands disappeared and that of the newly formed intense thiazoline C=N band appeared at 1650 cm<sup>-1</sup>. Moreover, the NMR spectra displayed a singlet of one proton at 6.30 which is assigned to C<sub>5</sub>-H thiazoline ring.

#### PHARMACOLOGICAL EVALUATION

The antidiabetic activity of the synthesized compounds in Tables II & III in addition to the intermediate thiourea, 13 is tested by determining the plasma glucose level using glucose peroxide technique (Boutwell, 1961). Unfortunately compound 13 showed a weak hypoglycemic activity while none of the other tested

Scheme

compounds showed any significant hypoglycemic effect. The initial pharmacological screening of these compounds in rats revealed that some of these compounds possessed the ability to induce cardiac depressant response.

Thus, intravenous administration of the synthesized compounds in Table II & III in the doses of 7.5 and 15 µmol Kg<sup>-1</sup> into the anaesthetized rats produced dose-dependent decreases in the heart rate. Some of these compounds did not significantly affect the heart rate when tested at the dose level of 7.5 µmol Kg<sup>-1</sup>, see Table IV. Compounds No. 23, 22 and 20 did not exert any significant negative chronotropic effects when tested at the dose of 15  $\mu$ mol Kg<sup>-1</sup>. The mean $\pm$  s.e.m. percentage decreases in the heart rate induced by each compound are shown in Table IV. The most potent compounds seems to be No. 6, 9 and 7 and the duration of action of the tested compounds range from onee to 6 min. The longest duration was shown by compounds 6, 9 and 9, respectively. The mean ± s.e.m. durations for the different compounds are shown in Table IV.

From the above findings, potent cardiac depressant responses were observed with compounds having the thiazolidin-4-one moiety and large aliphatic or alicylic side chain at position -3 with one methylene bridge between the acetylamino group and the aromatic ring as seen for compounds **6** & **7**. On the other hand, the replacement of thiazolidine-4-one with thiazoline ring with 4-bromophenyl substituents and large aliphatic or alicylic side chain at the position--3 with two

**Table IV.** Effect of the synthesized compounds 14-29 on the basal heart rate and duration of action

Comp. No.	Percentage dec rate (H.R.) Mea	Duration(min) after 15 μmol/		
	7.5 μmol/Kg <sup>-1</sup>	15 μmol/Kg <sup>-1</sup>	— Kg <sup>−1</sup>	
14	5.5± 3.1	23.4± 4.8	10± 2.0	
15	0	17.4± 5.1	$4 \pm 0.5$	
16	$31.7 \pm 4.8$	$73.9 \pm 5.6$	$16 \pm 4.1$	
17	$2.5\pm1.2$	$62.9 \pm 7.3$	5±1.2	
18	$29.6 \pm 4.4$	$37.9 \pm 3.8$	$3 \pm 0.4$	
19	$13.3 \pm 3.9$	$63.9 \pm 7.2$	15± 2.9	
20	0	0	$1 \pm 0.5$	
21	$8.1 \pm 3.4$	$31.8 \pm 6.3$	$15 \pm 1.4$	
22	0	$7.5 \pm 3.1$	$1.5 \pm 0.4$	
23	0	$3.9 \pm 2.5$	$2 \pm 0.1$	
24	$3.5 \pm 1.3$	$13.4 \pm 4.6$	$2 \pm 0.1$	
25	$5.0 \pm 2.1$	$39.5 \pm 9.5$	$2 \pm 0.6$	
26	0	0	_	
27	$28.9 \pm 3.4$	$36.4 \pm 3.9$	$4 \pm 0.3$	
28	$1.1 \pm 0.5$	$23.2 \pm 4.2$	$1 \pm 0.5$	
29	$37.1 \pm 4.5$	$49.8 \pm 6.9$	$15 \pm 3.1$	

methylene bridge between the acetylamino and aromatic ring resulted in an decrease in activity as seen for compounds 6, 8.

Also, it is clear that the substitution of thiazoline ring with 4-bromophenyl moiety resulted in a significant decrease in the duration of action.

#### REFERENCES CITED

Bott-Handford, R. and Heath, H., The effects of aldose

- reductase inhibitors on thee metabolism of cultured monkey kidney epithelial cells. *Biochem. Pharmacol.* 30, 3065 (1981).
- Bott-Handford, R. and Heath, H., Identification of fractose as the retinopathic agent associated with the ingestion of sucrose-rich diets in the rate. *Metabolism*, 29, 1247 (1980).
- Boutwell, J. H. Jr., Clin. Chem. Lab. Manual and Method, Philadelphia Lea & Febriger, 1961, pp. 283.
- El-Kerdawy, M. M. and El-Kousy, S., Preparation of certain 1[4-(acetamidomethyl) bmrenesulfonyl urea] and thiourea derivatives. *Bull. Fac. Pharm. Cairo Univ.* 12, 248 (1975).
- Eltahir, K. E. H., Al-Obeid, H. A., Al-Rashood, K. A.,

- Madani, A. E. and Ageel, A. M., The antiarrhythmic activity of N-alkyl-1,2-dipheenylethanolamines. *Pharmac. Res.* 6, 252 (1989).
- Hoechst, F., Preparation of sulfonylureas. *Chem. Abstr.* 62, 6131h (1965).
- Peterson, U. J., Sarges, R., Aldinger, C. E. and MacDonald, D. P., A novel aldose reductase inhibitors that inhibits polyol pathway activity in diabetic and galactosenic rates. *Metabolism*, 28, 456 (1979).
- Sohda, T., Mizuno, K., Imamiya, E., Sugiyama, Y., Fujita, T. and Kawamatsu, Y., Studies on antidiabetic agents 11. Synthesis of 5-[4-(1-methyl cyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione and its derivatives. *Chem. Pharm. Bull.* 30, 3580 (1982).